Bone marrow-derived mesenchymal stem cells (bMSCs) contribute to tissue repair and regeneration. Cell fusion between somatic cells and bMSCs to form hybrid cells may have an important role in tissue repair through the subsequent reprogramming of the somatic cell nucleus. Few studies have assessed the mesenchymal characteristics of fusion-induced hybrid cells and their survival mechanisms. In this study, we investigated the effect of cell fusion on the biological characteristics of pancreatic ductal cells (PDCs) and on the survival mechanism of hybrid cells. To this end, we generated mouse-mouse hybrid cells in vitro by polyethylene glycol-mediated fusion of primary mouse bMSCs with primary mouse PDCs. Hybrid cells showed an enhanced capacity for proliferation and self-renewal compared with PDCs. No PDC had the capacity for anchorage-independent growth or invasion into Matrigel, but some hybrid cells were able to form colonies in soft agar and invade Matrigel. Expression of the tumor suppressor protein p53, which initiates apoptosis, was detected in hybrid cells but not in PDCs or bMSCs. However, the p53 deacetylase, sirtuin 1 (SIRT1), was also detected in hybrid cells, and the level of acetylated p53, the active form, was low. The addition of nicotinamide (Nam) inhibited the deacetylation activity of SIRT1 on p53 and induced cell apoptosis in hybrid cells. This study demonstrated that PDCs could obtain high proliferation rates, self-renewal capabilities, and mesenchymal characteristics by fusion with bMSCs. SIRT1 expression in the hybrid cells attenuated their apoptosis.

Keywords:
Pancreatic ductal cells, Mesenchymal stem cells, Cell fusion, p53, SIRT1
1.
Blau, H.M., B.T. Blakely (1999) Plasticity of cell fate: insights from heterokaryons. Semin Cell Dev Biol 10: 267–272.
2.
Bunn, C.L., G.M. Tarrant (1980) Limited lifespan in somatic cell hybrids and cybrids. Exp Cell Res 127: 385–396.
3.
Chamberlain, G., J. Fox, B. Ashton, J. Middleton (2007) Concise review: mesenchymal stem cells – their phenotype, differentiation capacity, immunological features, and potential for homing. Stem Cells 25: 2739–2749.
4.
Fujiwara, T., M. Bandi, M. Nitta, E.V. Ivanova, R.T. Bronson, D. Pellman (2005) Cytokinesis failure generating tetraploids promotes tumorigenesis in p53-null cells. Nature 437: 1043–1047.
5.
Guerardel, C., S. Deltour, S. Pinte, D. Monte, A. Begue, A.K. Godwin, D. Leprince (2001) Identification in the human candidate tumor suppressor gene HIC-1 of a new major alternative TATA-less promoter positively regulated by p53. J Biol Chem 276: 3078–3089.
6.
Houghton, J., C. Stoicov, S. Nomura, A.B. Rogers, J. Carlson, H. Li, X. Cai, J.G. Fox, J.R. Goldenring, T.C. Wang (2004) Gastric cancer originating from bone marrow-derived cells. Science 306: 1568–1571.
7.
Islam, M.Q., S. Meirelles Lda, N.B. Nardi, P. Magnusson, K. Islam (2006) Polyethylene glycol-mediated fusion between primary mouse mesenchymal stem cells and mouse fibroblasts generates hybrid cells with increased proliferation and altered differentiation. Stem Cells Dev 15: 905–919.
8.
Josse, C., R. Schoemans, N.A. Niessen, M. Delgaudine, A.C. Hellin, C. Herens, P. Delvenne, V. Bours (2010) Systematic chromosomal aberrations found in murine bone marrow-derived mesenchymal stem cells. Stem Cells Dev 19: 1167–1173.
9.
Kritzik, M.R., T. Krahl, A. Good, M. Krakowski, L. St-Onge, P. Gruss, C. Wright, N Sarvetnick (2000) Transcription factor expression during pancreatic islet regeneration. Mol Cell Endocrinol 164: 99–107.
10.
Lluis F., M.P. Cosma (2010) Cell-fusion-mediated somatic-cell reprogramming: a mechanism for tissue regeneration. J Cell Physiol 223: 6–13.
11.
Luo, J., A.Y. Nikolaev, S. Imai, D. Chen, F. Su, A. Shiloh, L. Guarente, W. Gu (2001) Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell 107: 137–148.
12.
Matsumura, H., T. Tada (2008) Cell fusion-mediated nuclear reprogramming of somatic cells. Reprod Biomed Online 16: 51–56.
13.
Menendez, S., S. Camus, J.C. Izpisua Belmonte (2000) p53: guardian of reprogramming. Cell Cycle 9: 3887–3891.
14.
Meulmeester, E., A.G. Jochemsen (2008) p53: a guide to apoptosis. Curr Cancer Drug Targets 8: 87–97.
15.
Ogle, B.M., M. Cascalho, J.L. Platt (2005) Biological implications of cell fusion. Nat Rev Mol Cell Biol 6: 567–575.
16.
Oren-Suissa, M., B. Podbilewicz (2007) Cell fusion during development. Trends Cell Biol 17: 537–546.
17.
Polyak, K., T. Waldman, T.C. He, K.W. Kinzler, B. Vogelstein (1996) Genetic determinants of p53-induced apoptosis and growth arrest. Genes Dev 10: 1945–1952.
18.
Pomerantz, J., H.M. Blau (2004) Nuclear reprogramming: a key to stem cell function in regenerative medicine. Nat Cell Biol 6: 810–816.
19.
Rosenberg, L., A.I. Vinik (1989) Induction of endocrine cell differentiation: a new approach to management of diabetes. J Lab Clin Med 114: 75–83.
20.
Shi, Q., R.W. King (2005) Chromosome nondisjunction yields tetraploid rather than aneuploid cells in human cell lines. Nature 437: 1038–1042.
21.
Sun, S., Z. Guo, X. Xiao, B. Liu, X. Liu, P.H. Tang, N. Mao (2003) Isolation of mouse marrow mesenchymal progenitors by a novel and reliable method. Stem Cells 21: 527–535.
22.
Sutton, R., P. Hammonds, D. Hughes, A. Clark, D.W. Gray, P.J. Morris (1990) Human pancreatic islet isolation with increased incubation temperatures and variable density gradients. Transplant Proc 22: 758–759.
23.
Terada, N., T. Hamazaki, M. Oka, M. Hoki, D.M. Mastalerz, Y. Nakano, E.M. Meyer, L. Morel, B.E. Petersen, E.W. Scott (2002) Bone marrow cells adopt the phenotype of other cells by spontaneous cell fusion. Nature 416: 542–545.
24.
Tropel P., D. Noel, N. Platet, P. Legrand, A.L. Benabid, F. Berger (2004) Isolation and characterisation of mesenchymal stem cells from adult mouse bone marrow. Exp Cell Res 295: 395–406.
25.
Trusolino, L., A. Bertotti, P.M. Comoglio (2010) MET signalling: principles and functions in development, organ regeneration and cancer. Nat Rev Mol Cell Biol 11: 834–848.
26.
Vassilopoulos G., P.R. Wang, D.W. Russell (2003) Transplanted bone marrow regenerates liver by cell fusion. Nature 422: 901–904.
27.
Vaziri, H., S.K. Dessain, E. Ng Eaton, S.I. Imai, R.A. Frye, T.K. Pandita, L. Guarente, R.A. Weinberg (2001) hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell 107: 149–159.
28.
Wales, M.M., M.A. Biel, W. el Deiry, B.D. Nelkin, J.P. Issa, W.K. Cavenee, S.J. Kuerbitz, S.B. Baylin (1995) p53 activates expression of HIC-1, a new candidate tumour suppressor gene on 17p13.3. Nat Med 1: 570–577.
29.
Wang, X., H. Willenbring, Y. Akkari, Y. Torimaru, M. Foster, M. Al-Dhalimy, E. Lagasse, M. Finegold, S. Olson, M. Grompe (2003) Cell fusion is the principal source of bone-marrow-derived hepatocytes. Nature 422: 897–901.
30.
Weimann, J.M., C.B. Johansson, A. Trejo, H.M. Blau (2003) Stable reprogrammed heterokaryons form spontaneously in Purkinje neurons after bone marrow transplant. Nat Cell Biol 5: 959–966.
31.
Xu, X., J. D’Hoker, G. Stange, S. Bonne, N. De Leu, X. Xiao, M. Van de Casteele, G. Mellitzer, Z. Ling, D. Pipeleers, L. Bouwens, R. Scharfmann, G. Gradwohl, H. Heimberg (2008) Beta cells can be generated from endogenous progenitors in injured adult mouse pancreas. Cell 132: 197–207.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.